series-a
Stage
2025
Founded
1
Investors
About
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing transformational therapies for autoimmune diseases. Its lead program, CM313, is an IgG1 monoclonal antibody targeting CD38, designed to modulate multiple arms of the immune system for rapid and durable responses in conditions like Immune Thrombocytopenia and Systemic Lupus Erythematosus.
Explore Timberlyne Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.